BackOno Pharmaceutical , Ltd. Overview

Ono Pharmaceutical , Ltd. Receivables

Ono Pharmaceutical , Ltd.'s receivables is $130B.

Get informed when a big investor buys or sells

+ Follow
Receivables
$130.05B
↓ 9.40% YoYΔ $-13.49B vs prior year quarter

Peer trimmed avg / median

Loading

Ono Pharmaceutical , Ltd. Receivables History

Loading

Ono Pharmaceutical , Ltd. vs. peers: Receivables Comparison

Loading

Ono Pharmaceutical , Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Ono Pharmaceutical , Ltd. (OPHLY) FAQ

As of the most recent data (June 2026), OPHLY shows a receivables of $130B. That compares with $140B in the prior-year period — down 9.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, OPHLY's receivables is now $130B (was $140B) — a 9.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Ono Pharmaceutical , Ltd. is outperforming or lagging.

Tracking OPHLY's receivables over time shows whether Ono Pharmaceutical , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $130B That compares with $140B in the prior-year period — down 9.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Ono Pharmaceutical , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $130B) with ownership activity and broader fundamentals.